EP Patent

EP3250230B9 — Modulators of complement activity

Assigned to UCB Inc · Expires 2022-02-23 · 4y expired

What this patent protects

Patent listed against zilucoplan-sodium.

Drugs covered by this patent

zilucoplan-sodium (ZILUCOPLAN SODIUM)

Patent Metadata

Patent number: EP3250230B9
Jurisdiction: EP
Classification: —
Expires: 2022-02-23
Drug substance claim: No
Drug product claim: No
Assignee: UCB Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.